2003-2013, a valuable study: Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage IV breast cancer
| Autor: | Lizhi Niu, Kecheng Xu, Mao Lin, Jiongyuan Xu, Shuzhen Liang, Yong Hu, Youyong Lv, Zhu Weibing, Qian Wei, Zhanchun Zhou, Jibing Chen, Feng Jiang |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Oncology Adult medicine.medical_specialty medicine.medical_treatment Immunology Breast Neoplasms Kaplan-Meier Estimate Cancer Vaccines 03 medical and health sciences 0302 clinical medicine Immune system Breast cancer Cytokine-Induced Killer Cells Antigen Antigens Neoplasm Internal medicine Immunology and Allergy Medicine Humans Lymphocyte Count Neoplasm Metastasis Aged Neoplasm Staging Proportional Hazards Models Retrospective Studies Chemotherapy Cytokine-induced killer cell biology business.industry Immunotherapy Dendritic cell Dendritic Cells Middle Aged medicine.disease Combined Modality Therapy 030104 developmental biology Treatment Outcome 030220 oncology & carcinogenesis biology.protein Cytokines Female Antibody business |
| Zdroj: | Immunology letters. 183 |
| ISSN: | 1879-0542 |
| Popis: | Dendritic cells (DCs) and cytokine-induced killer (CIK) cells have both shown activity as immunotherapy in some malignancies. Our aim was to prospective assess the effect of this immunotherapy in patients with stage IV breast cancer. Between Aug 2003 and Dec 2013, we collected 368 patients who met inclusion criteria and divided into immunotherapy group (treatment group: 188 patients) and chemotherapy group (control group: 180 patients). DCs were prepared from the mononuclear cells isolated from patients in the treatment group using IL-2/GM-CSF and were loaded with tumour antigens; CIK cells were prepared by incubating peripheral blood lymphocytes with IL-2, IFN-γ, and CD3 antibodies. After the patients had received low-dose chemotherapy, those in the treatment group also received the DC-CIK therapy, which was repeated four times in a fortnight to form one cycle. At least three cycles of DC-CIK therapy were given. Immune function was measured in treatment group patients' sera. Disease-free survival (DFS) and Overall survival (OS) after the diagnosis of stage IV breast cancer was assessed after a 10-year follow-up. The result demonstrated that immune function is obviously enhanced after DC-CIK therapy. By Cox regression analysis, DC-CIK therapy reduced the risk of disease progression (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect